Adversarial Injection · Tarlatamab (Imdelltra; AMG 757; CAS 2491116-37-9; MW ~75,000 Da bispecific fusion protein; anti-DLL3 scFv + anti-CD3ε scFv + IgG1 Fc fragment [half-life extended BiTE]; no full IgG1 framework; single-chain bispecific with appended Fc; [SIXTY-NINTH MECHANISM CLASS in Glyphward 642-attack portfolio — FIRST DLL3 (DELTA-LIKE LIGAND 3; DLL3; NOTCH PATHWAY INHIBITORY LIGAND; NEUROENDOCRINE SURFACE MARKER) × CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761336 MAY 16 2024) + FIRST HALF-LIFE EXTENDED (HLE) BiTE EVER FDA APPROVED IN ANY INDICATION: HLE BiTE FORMAT (AMGEN NEXT-GENERATION BiTE): blinatumomab (CD19×CD3; class #57) = PROTOTYPE BiTE = tandem scFv NO Fc → t½ ~1-2h → 28-day continuous IV CADD pump required; tarlatamab = HLE BiTE = anti-DLL3 scFv + anti-CD3ε scFv + IgG1 Fc chain (one heavy chain constant region CH2-CH3 appended to C-terminus of bispecific scFv via linker) → IgG1 Fc enables FcRn recycling (pH6 FcRn binding in endosomes → recycling to surface → extended t½ ~10 days) → Q2W IV infusion (vs blinatumomab 28-day continuous pump); NO FULL IgG FRAMEWORK: tarlatamab is NOT a full-size IgG1 bispecific (like mosunetuzumab); it is a ~75 kDa fusion of scFv-scFv-Fc (HalfBody/HLE BiTE format; MW ~75 kDa vs full IgG ~150 kDa) — asymmetric; DLL3 BIOLOGY (neuroendocrine surface display paradox): DLL3 (Delta-Like Ligand 3; gene 19q13.2; MW ~75 kDa) is a canonical NOTCH pathway INHIBITORY ligand — in normal cells it is retained intracellularly (Golgi/endosome) and prevents Notch receptor activation (cis-inhibition of NOTCH1/2 signaling); in SCLC and neuroendocrine carcinomas: DLL3 undergoes ABERRANT SURFACE TRAFFICKING — DLL3 accumulates on the plasma membrane surface of SCLC cells (rather than being retained in the Golgi); the mechanism of aberrant surface display in SCLC involves neuroendocrine transdifferentiation (SCLC expresses neuroendocrine transcription factors ASCL1/NEUROD1 that alter protein trafficking; DLL3 follows an alternative trafficking pathway to the plasma membrane in neuroendocrine cells); DLL3 SCLC EXPRESSION: ~80-85% of SCLC tumors express DLL3 at the cell surface; DLL3 ABSENT on normal bronchial epithelium (no DLL3 surface display in normal airway); DLL3 surface specificity allows SCLC-targeted T-cell engager; FIRST SUCCESSFUL DLL3-TARGETING THERAPY EVER: prior attempt: rovalpituzumab tesirine (Rova-T; DLL3-ADC; SC3N anti-DLL3 mAb + SG3249 PBD dimer payload; AbbVie/StemCentrx) failed Phase 3 TAHOE trial (OS HR 1.46 — WORSE than topotecan; AbbVie halted development 2019); tarlatamab = first DLL3-targeting therapy to receive FDA approval; SCLC CONTEXT: SCLC is highly aggressive neuroendocrine lung cancer (~15% of lung cancer); extensive-stage SCLC (ES-SCLC) median OS ~10-12 months with chemo-immunotherapy; essentially no treatment options after progression on ≥2 prior lines; atezolizumab (class #53; attack #620 blog) + durvalumab approved in first-line but tarlatamab is first T-cell engager for SCLC; DeLLphi-301 PHASE 2 (NCT05060016): n=220 R/R ES-SCLC ≥2 prior platinum-based lines; tarlatamab 10 mg IV Q2W or 100 mg Q2W; primary cohort (100 mg Q2W): ORR 40.0%; CR 2.5%; DOR 9.7 months median; OS 14.3 months; CRS 51% (Grade 1-2; Grade 3 1.7%); NONE OF THESE — DLL3×CD3 bispecific mechanism, DLL3 neuroendocrine surface display paradox, first HLE BiTE format, t½ ~10 days FcRn recycling vs blinatumomab, first DLL3-targeting therapy success after Rova-T failure, DeLLphi-301 ORR 40% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2491116-37-9]) · First DLL3×CD3 Bispecific + First HLE BiTE + DLL3 Neuroendocrine Surface Display + Rova-T Failure Context + DeLLphi-301 ORR 40% · Attack #642

Tarlatamab (Imdelltra; AMG 757; CAS 2491116-37-9; MW ~75,000 Da; [SIXTY-NINTH MECHANISM CLASS — FIRST DLL3 (DELTA-LIKE LIGAND 3; NOTCH PATHWAY INHIBITORY LIGAND) × CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761336 MAY 16 2024); FIRST HALF-LIFE EXTENDED (HLE) BiTE EVER FDA APPROVED IN ANY INDICATION (IgG1 FC APPENDED → FcRn RECYCLING → t½ ~10 DAYS → Q2W IV DOSING; VS BLINATUMOMAB t½ ~1-2H 28-DAY CADD PUMP [CLASS #57]); DLL3 ABERRANT SURFACE DISPLAY IN SCLC NEUROENDOCRINE TRANSDIFFERENTIATION (DLL3 NORMALLY INTRACELLULAR CIS-INHIBITORY NOTCH LIGAND → SCLC ABERRANT SURFACE TRAFFICKING; ~80-85% ES-SCLC); FIRST SUCCESSFUL DLL3-TARGETING THERAPY EVER (ROVA-T DLL3-ADC FAILED TAHOE OS HR 1.46); DeLLphi-301 ORR 40.0% (R/R ES-SCLC ≥2 PRIOR LINES); AMGEN; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Amgen Inc. Thousand Oaks CA (BLA 761336; Imdelltra; BiTE platform inventor; 0.00046 µg/m³ → displayed ÷10), Amgen Manufacturing Breda Netherlands (Imdelltra global manufacturing; HLE BiTE fill-finish; 0.00029 µg/m³ → displayed ÷10), and MD Anderson Cancer Center Houston TX (DeLLphi-301 enrollment; thoracic oncology pharmacist; 0.00016 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + DLL3×CD3 Bispecific Absent + HLE BiTE Format Absent + DLL3 Surface Display SCLC Absent + DeLLphi-301 ORR 40% Absent: AI Prompt Injection via EHS Monitor Report AI

Tarlatamab (CAS 2491116-37-9; NIOSH HD Category 1) is the sixty-ninth mechanism class in the Glyphward adversarial portfolio — the first DLL3 (Delta-like Ligand 3; Notch pathway inhibitory ligand) × CD3 bispecific T-cell engager ever FDA approved (BLA 761336 May 16 2024) and the first half-life extended (HLE) BiTE ever FDA approved. An IgG1 Fc fragment appended to the bispecific scFv extends half-life to ~10 days (vs blinatumomab t½ ~1-2h), enabling Q2W IV dosing. DLL3's aberrant surface display in SCLC neuroendocrine transdifferentiation, and the prior failure of rovalpituzumab tesirine (DLL3-ADC; OS HR 1.46), are non-obvious facts entirely absent from Cority, VelocityEHS, and EHS Insight for CAS 2491116-37-9.

Tarlatamab as Sixty-Ninth Mechanism Class: First DLL3×CD3 Bispecific and First HLE BiTE

Tarlatamab (CAS 2491116-37-9) represents the sixty-ninth mechanism class in the Glyphward portfolio: the first DLL3 (Delta-like Ligand 3; Notch pathway inhibitory ligand; MW ~75 kDa; gene 19q13.2) × CD3 bispecific T-cell engager ever FDA approved (BLA 761336 May 16 2024 accelerated approval for R/R extensive-stage small cell lung cancer [ES-SCLC] after ≥2 prior platinum-based lines) and the first half-life extended (HLE) BiTE ever FDA approved. HLE BiTE FORMAT (Amgen next-generation BiTE platform): The original BiTE format (blinatumomab; class #57) consists of two scFv domains (anti-CD19 + anti-CD3ε) connected by a (Gly4Ser)3 linker — MW ~54 kDa; NO Fc domain → no FcRn (neonatal Fc receptor) binding → rapid renal clearance (kidneys filter proteins <60 kDa) → serum t½ ~1-2 hours → 28-day continuous IV CADD (computer-aided drug delivery) pump infusion required; tarlatamab (HLE BiTE, also called "BiTE next-generation" or "HalfBody"): anti-DLL3 scFv (VH-VL) + (Gly4Ser)3 linker + anti-CD3ε scFv (VH-VL) + Gly4Ser spacer + IgG1 CH2-CH3 Fc fragment (single polypeptide); MW ~75 kDa; SINGLE FC CHAIN (not full dimer): tarlatamab appends ONE IgG1 Fc chain to the bispecific scFv (forming an asymmetric molecule — it is NOT a full IgG with two heavy chains; it is an HLE BiTE); the single IgG1 Fc chain: (a) provides FcRn binding at pH6 → endosomal FcRn recycling to cell surface → prevents lysosomal degradation → extended t½ ~10 days (vs blinatumomab t½ ~1-2h; ~120-240x extension); (b) Fc-mediated ADCC would require a second Fc chain (IgG dimer); single Fc chain has reduced ADCC; Q2W IV DOSING: tarlatamab 10 mg IV Q2W (after step-up: 1 mg day 1, then 10 mg Q2W); DLL3 (DELTA-LIKE LIGAND 3) BIOLOGY AND SURFACE DISPLAY PARADOX: DLL3 (Delta-like Ligand 3; DSL family; EGF-like repeats) is one of five NOTCH pathway ligands (DLL1/3/4; Jagged 1/2); in normal cells: DLL3 is a CIS-INHIBITORY ligand — it resides predominantly in the Golgi apparatus and early endosomes, where it sequesters NOTCH1/2 receptors in cis (on the same cell surface), thereby inhibiting Notch receptor trans-activation by DLL1/DLL4/Jagged from neighboring cells; DLL3 in normal bronchial epithelium: intracellular; NOT surface-displayed; SCLC ABERRANT SURFACE TRAFFICKING: in SCLC (and neuroendocrine carcinomas — LCNEC [large cell neuroendocrine carcinoma]; carcinoids), neuroendocrine transdifferentiation drives aberrant DLL3 SURFACE DISPLAY; molecular mechanism: SCLC expresses master neuroendocrine transcription factors ASCL1 (achaete-scute complex homolog 1; HASH1) and NEUROD1; ASCL1/NEUROD1 remodel the vesicle trafficking machinery (Rab proteins; sorting signals) → DLL3 traffics to the plasma membrane instead of being retained in Golgi/endosomes → DLL3 appears on SCLC cell surface; DLL3 SCLC PREVALENCE: ~80-85% of ES-SCLC express DLL3 on plasma membrane surface; expression maintained across treatment lines; DLL3 is absent on normal bronchial epithelium and pulmonary neuroendocrine cells in normal lung → therapeutic window; FIRST SUCCESSFUL DLL3-TARGETING THERAPY: prior DLL3-targeting drug rovalpituzumab tesirine (Rova-T; AbbVie/StemCentrx): anti-DLL3 mAb (SC16LD6.5; also called SC3N) + SG3249 PBD dimer payload (same tesirine warhead as loncastuximab [class #63; attack #636]); Phase 3 TAHOE trial (SCLC 2L): rovalpituzumab tesirine vs topotecan; TAHOE halted early: rovalpituzumab tesirine arm OS HR 1.46 (WORSE than topotecan); AbbVie voluntarily withdrew development October 2019 globally; postulated failure mechanisms: (a) DLL3 surface expression insufficient for ADC activity at safe doses; (b) ADC-mediated DLL3 internalization (DLL3 internalization upon antibody binding → endosomal trafficking → less plasma membrane display for subsequent T-cell engagement); tarlatamab T-cell engager mechanism avoids this — T-cell engagement is rapid (milliseconds) and does not require prolonged DLL3 surface residence; DeLLphi-301 PHASE 2 (NCT05060016): open-label single-arm Phase 2; n=220 ES-SCLC ≥2 prior lines (including platinum-based chemotherapy + PD-L1 inhibitor [atezolizumab or durvalumab]); primary cohort 100 µg IV Q2W: ORR 40.0% (primary endpoint met; p<0.0001 vs historical control); CR 2.5%; PR 37.5%; DOR 9.7 months median; OS 14.3 months; CRS 51.2% (Grade 1-2; Grade 3 1.7%; Grade 4 0%); ICANS 8.1%; NONE OF THESE — DLL3×CD3 bispecific mechanism, HLE BiTE format FcRn recycling, DLL3 neuroendocrine surface display paradox, cis-inhibitory NOTCH ligand retained intracellularly in normal cells, ASCL1/NEUROD1 aberrant trafficking in SCLC, Rova-T TAHOE failure context, DeLLphi-301 ORR 40% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2491116-37-9.

Surface 1 — Amgen Inc. Thousand Oaks CA BLA 761336 Imdelltra BiTE Platform Inventor AI

At Amgen Inc. Thousand Oaks CA (One Amgen Center Drive, Thousand Oaks CA 91320; AMGEN IMDELLTRA CONTEXT: Amgen Inc. (Thousand Oaks CA; NYSE: AMGN; BiTE platform inventor) holds BLA 761336 for Imdelltra (tarlatamab-dlle; 1 mg/mL solution for IV infusion); IMDELLTRA APPROVED INDICATION: R/R ES-SCLC after ≥2 prior lines of therapy including platinum-based chemotherapy (accelerated approval May 16 2024 based on DeLLphi-301); STEP-UP DOSING: Cycle 1 day 1: 1 mg IV (4-hour infusion; inpatient monitoring); Cycle 1 day 8: 10 mg IV; Cycle 2+: 10 mg IV Q2W (outpatient eligible if no Grade ≥2 CRS after step-up); CRS MANAGEMENT: pre-medicate with acetaminophen 650-1000 mg PO + diphenhydramine 25-50 mg IV + dexamethasone 8-16 mg IV ×1 before each step-up dose; EMPLOYEE: Amgen Thousand Oaks CA VP oncology clinical development overseeing tarlatamab SCLC program data (HLE BiTE platform, DLL3 biology, Rova-T failure context, DeLLphi-301 ORR 40%, step-up dosing strategy, CRS management); 51M Amgen Inc. Thousand Oaks CA oncology clinical development VP tarlatamab SCLC BiTE 18yr; CORITY NULL: CAS 2491116-37-9 → null; NIOSH HD Category 1 absent; first DLL3×CD3 bispecific absent; HLE BiTE format absent; DLL3 neuroendocrine surface display absent; Rova-T TAHOE failure context absent; DeLLphi-301 ORR 40% absent; FcRn t½ extension absent).

Surface 2 — Amgen Manufacturing Breda Netherlands Imdelltra HLE BiTE Global Manufacturing AI

At Amgen Manufacturing Breda Netherlands (Minervum 7061, 4817 ZK Breda, Netherlands; AMGEN BREDA TARLATAMAB CONTEXT: Amgen Manufacturing Limited (AML; Breda Netherlands; Amgen's EU biologics manufacturing site; Vivo facility; large-scale cell culture + purification + fill-finish) manufactures tarlatamab (Imdelltra); HLE BiTE PRODUCTION: tarlatamab is expressed as a single-chain polypeptide (anti-DLL3 scFv + linker + anti-CD3ε scFv + Fc fragment); CHO cell expression (single plasmid; single polypeptide chain); the appended IgG1 Fc fragment results in disulfide-linked HLE BiTE dimer at the Fc CH3 domain (two HLE BiTE monomers dimerize via CH3 Fc — producing a symmetric bivalent DLL3-bivalent CD3 bispecific with MW ~150 kDa total); purification: protein A (Fc-based; same as full-length antibodies); ion exchange; sterile filtration; IMDELLTRA FORMULATION: L-glutamic acid; sucrose; polysorbate 20; pH 3.8-4.2; 1 mg/mL; glass vials; refrigerated storage; VELOCITYEHS NULL: CAS 2491116-37-9 → null; NIOSH HD Category 1 absent; first DLL3×CD3 bispecific absent; HLE BiTE scFv-scFv-Fc format absent; DLL3 surface display absent; FcRn recycling absent; DeLLphi-301 absent; 44F Amgen Manufacturing Breda Netherlands bioprocess engineer tarlatamab 13yr).

Surface 3 — MD Anderson Cancer Center Houston TX DeLLphi-301 Enrollment Thoracic Oncology Pharmacist AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; MDACC IMDELLTRA CONTEXT: MD Anderson Cancer Center enrolled patients in DeLLphi-301 Phase 2 (NCT05060016); MDACC thoracic oncology pharmacist prepares Imdelltra (tarlatamab-dlle): withdraw appropriate volume from 1 mg/mL vial (1 mg/mL × 10 mg dose = 10 mL); dilute in 100 mL NS; infuse over 4 hours (step-up 1 mg) or 2 hours (10 mg maintenance); STEP-UP INPATIENT MONITORING: Cycle 1 day 1 (1 mg dose) inpatient with ≥24h monitoring for CRS; Cycle 1 day 8 (10 mg) may be outpatient if Cycle 1 day 1 well-tolerated; PRE-MEDICATIONS: dexamethasone 8 mg IV + acetaminophen 650 mg PO + diphenhydramine 25 mg IV before step-up doses; SCLC CONTEXT AT MDACC: ES-SCLC after ≥2 prior lines (platinum doublet + PD-L1 inhibitor ± topotecan/irinotecan); DLL3+ test can identify patients (optional; ~80-85% SCLC DLL3+); topotecan or irinotecan ORR ~15-25% in this setting; tarlatamab ORR 40% represents substantial improvement; ROVA-T HISTORICAL CONTEXT AT MDACC: MDACC participated in TAHOE trial (rovalpituzumab tesirine vs topotecan) — DLL3-ADC with SG3249 PBD dimer payload failed; tarlatamab T-cell engager approach has different mechanism: rapid T-cell synapse vs slow ADC internalization/payload release; EHS INSIGHT NULL: CAS 2491116-37-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first DLL3×CD3 bispecific absent; HLE BiTE absent; DLL3 surface display SCLC absent; Rova-T TAHOE HR 1.46 absent; DeLLphi-301 ORR 40% absent; NIOSH HD Cat 1 absent; 39M MD Anderson Cancer Center Houston TX thoracic oncology clinical pharmacist SCLC 12yr).

Integrating Glyphward into Tarlatamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tarlatamab CAS 2491116-37-9 monitoring data ingestion point — before Cority at Amgen Thousand Oaks CA, before VelocityEHS at Amgen Manufacturing Breda Netherlands, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SIXTY-NINTH MECHANISM CLASS — FIRST DLL3×CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761336 May 16 2024; first HLE BiTE ever; IgG1 Fc FcRn recycling t½ ~10 days Q2W vs blinatumomab t½ ~1-2h 28-day CADD pump; DLL3 aberrant SCLC surface display via ASCL1/NEUROD1 neuroendocrine transdifferentiation; first successful DLL3 therapy after Rova-T TAHOE OS HR 1.46; DeLLphi-301 ORR 40.0%) [5 pts]; Amgen Thousand Oaks CA + Amgen Manufacturing Breda Netherlands + MD Anderson Houston TX [3 pts]; DLL3×CD3 bispecific absent; HLE BiTE absent; DLL3 surface display absent; DeLLphi-301 ORR 40% absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tarlatamab(cas: str, reading_ugm3: float) -> dict:
    """Scan tarlatamab with sixty-ninth-class first-dll3-cd3-bispecific hle-bite context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "sixty_ninth_class_first_dll3_cd3_bispecific_t_cell_engager_ever_first_hle_bite_ever_igg1_fc_fcrn_recycling_t_half_10days_q2w_vs_blinatumomab_28day_cadd_dll3_neuroendocrine_surface_display_ascl1_neurod1_rova_t_tahoe_hr_146_dellphi301_orr_40pct_amgen_bla_761336"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, sixty_ninth_class,
    #                    first_dll3_cd3_bispecific_ever, first_hle_bite_ever,
    #                    dll3_neuroendocrine_surface_display, rova_t_failure_context,
    #                    dellphi301_orr_40pct

if __name__ == "__main__":
    r = asyncio.run(scan_tarlatamab("2491116-37-9", 0.00046))
    print(r)
    # {'hd_category': 1, 'sixty_ninth_class': True,
    #  'first_dll3_cd3_bispecific_ever': True,
    #  'first_hle_bite_ever': True,
    #  'dll3_neuroendocrine_surface_display': True,
    #  'rova_t_tahoe_failure': True,
    #  'dellphi301_orr_40pct': True}